New York and San Diego-based Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, has raised about $165 million for its IPO after pricing its 9.18 million shares at $18 per share.
HIG Capital’s Vernacare adds UK medical device businesses Bailey and ASep
58 minutes ago · 2 mins read
Paradigm Equity Partners acquires upholstery and performance fabric maker STI Fabrics
17 hours ago · 1 min read
KKR and Hildred merge diagnostics businesses Sapphiros and binx health into Onvaro
17 hours ago · 2 mins read
Eir Partners-backed Porter acquires health plan analytics firm Pareto Intelligence
17 hours ago · 1 min read
Bain Capital’s LeanTaaS snaps up hospital care transition platform Aidin
17 hours ago · 2 mins read
Carlyle-backed Vantive agrees hemodialysis business sale to Rockwell Medical
17 hours ago · 2 mins read
Novacap completes OSI Maritime Systems acquisition as first Fund VII deal
18 hours ago · 2 mins read
